ProCE Banner Activity

Current Treatment Landscape and Promising New Therapies for Patients With Prurigo Nodularis

Clinical Thought

While prurigo nodularis (PN) may be a result of several underlying conditions, it is a distinct clinical entity that may persist despite removal of the underlying cause. Dupilumab has been recently approved to manage PN and several other promising agents are in phase III trials. These options provide a much-needed therapeutic expansion to provide improved disease- and patient related outcomes.

Released: September 15, 2022

Share

Faculty

Benjamin Ungar

Benjamin Ungar, MD

Director, Alopecia Center of Excellence
Director, Rosacea & Seborrheic Dermatitis Clinic
Assistant Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Acknowledgement

This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte Corporation; Novartis Pharmaceuticals Corporation; and Sanofi and Regeneron Pharmaceuticals.

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Provided by

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Sanofi and Regeneron Pharmaceuticals

Target Audience

NPs and PAs

Disclosure

Primary Author

Benjamin Ungar, MD

Director, Alopecia Center of Excellence
Director, Rosacea & Seborrheic Dermatitis Clinic
Assistant Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Benjamin Ungar, MD: consultant/advisor/speaker: Bristol Myers Squibb, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, UCB.

Format

This program has been made available online.